These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 8492922)

  • 21. [Treatment of Parkinson's disease with levodopa and a dopa decarboxylase inhibitor].
    Londoõ R
    Neurol Neurocir Psiquiatr; 1976; 17(4):293-300. PubMed ID: 1018729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First clinical experience with levodopa/carbidopa microtablets in Parkinson's disease.
    Senek M; Hellström M; Albo J; Svenningsson P; Nyholm D
    Acta Neurol Scand; 2017 Dec; 136(6):727-731. PubMed ID: 28299787
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parkinson's disease and motor fluctuations: long-acting carbidopa/levodopa (CR-4-Sinemet).
    Goetz CG; Tanner CM; Klawans HL; Shannon KM; Carroll VS
    Neurology; 1987 May; 37(5):875-8. PubMed ID: 3574696
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial.
    Hauser RA; Hsu A; Kell S; Espay AJ; Sethi K; Stacy M; Ondo W; O'Connell M; Gupta S;
    Lancet Neurol; 2013 Apr; 12(4):346-56. PubMed ID: 23485610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease.
    Tetrud J; Nausieda P; Kreitzman D; Liang GS; Nieves A; Duker AP; Hauser RA; Farbman ES; Ellenbogen A; Hsu A; Kell S; Khanna S; Rubens R; Gupta S
    J Neurol Sci; 2017 Feb; 373():116-123. PubMed ID: 28131167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, double-dummy, placebo-controlled, crossover trial.
    Ondo WG; Shinawi L; Moore S
    Mov Disord; 2010 Dec; 25(16):2724-7. PubMed ID: 20925074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off.
    Koller W; Guarnieri M; Hubble J; Rabinowicz AL; Silver D
    J Neural Transm (Vienna); 2005 Feb; 112(2):221-30. PubMed ID: 15503197
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Controlled-release carbidopa-levodopa (Sinemet) in combination with standard Sinemet in advanced Parkinson's disease.
    Mark MH; Sage JI
    Ann Clin Lab Sci; 1989; 19(2):101-6. PubMed ID: 2665626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Melevodopa/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson's disease.
    Stocchi F; Zappia M; Dall'Armi V; Kulisevsky J; Lamberti P; Obeso JA;
    Mov Disord; 2010 Sep; 25(12):1881-7. PubMed ID: 20669296
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of a slow release preparation of levodopa on Parkinson's disease in combination with a peripheral decarboxylase inhibitor.
    Saarinen A; Myllylä VV; Tokola O; Hokkanen E
    Acta Neurol Scand; 1978 Dec; 58(6):340-9. PubMed ID: 369277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study].
    Litvinenko IV; Odinak MM; Mogil'naia VI; Sologub OS; Sakharovskaia AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(1):51-4. PubMed ID: 19156087
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels.
    Müller T; Erdmann C; Muhlack S; Bremen D; Przuntek H; Woitalla D
    Mov Disord; 2006 Mar; 21(3):332-6. PubMed ID: 16211593
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review.
    Wirdefeldt K; Odin P; Nyholm D
    CNS Drugs; 2016 May; 30(5):381-404. PubMed ID: 27138916
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease.
    LeWitt PA; Huff FJ; Hauser RA; Chen D; Lissin D; Zomorodi K; Cundy KC
    Mov Disord; 2014 Jan; 29(1):75-82. PubMed ID: 24339234
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.
    Block G; Liss C; Reines S; Irr J; Nibbelink D
    Eur Neurol; 1997; 37(1):23-7. PubMed ID: 9018028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease.
    Stocchi F; Fabbri L; Vecsei L; Krygowska-Wajs A; Monici Preti PA; Ruggieri SA
    Clin Neuropharmacol; 2007; 30(1):18-24. PubMed ID: 17272966
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease.
    Verhagen Metman L; Stover N; Chen C; Cowles VE; Sweeney M
    Mov Disord; 2015 Aug; 30(9):1222-8. PubMed ID: 25847690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Carbidopa and Levodopa Extended Release Capsules in Patients with and without Troublesome and Non-Troublesome Dyskinesia.
    Hauser RA; Zeitlin L; Fisher S; D'Souza R
    J Parkinsons Dis; 2020; 10(3):915-925. PubMed ID: 32568108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.
    Lowin J; Sail K; Baj R; Jalundhwala YJ; Marshall TS; Konwea H; Chaudhuri KR
    J Med Econ; 2017 Nov; 20(11):1207-1215. PubMed ID: 28895769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa.
    Othman AA; Rosebraugh M; Chatamra K; Locke C; Dutta S
    J Parkinsons Dis; 2017; 7(2):275-278. PubMed ID: 28211816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.